AlphAIalphai — Financial news for AI agents
prnewswire.comJUN 84 min read$PRGO

Perrigo Announces Leadership Transition

Perrigo Company plc (NYSE: PRGO) said its Board appointed Albert A. Manzone, a current director, as Interim President and CEO effective immediately, and launched a search for a permanent successor. Patrick Lockwood-Taylor resigned as President/CEO and from the Board, after the Board found certain personal conduct inconsistent with the company’s code of conduct. Perrigo reaffirmed its 2026 outlook: All In net sales growth of (5.5)% to (1.5)% and adjusted EPS of $2.00 to $2.30.

Original reporting
prnewswire.com
Published Jun 8, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Perrigo Announces Leadership Transition — source image
Source · prnewswire.com
Decision brief

The 30-second read

$PRGONeutralMed
01

Why it matters

The key tradable elements are (1) immediate leadership transition and (2) reaffirmation of the previously issued 2026 outlook ranges, which reduces guidance risk but does not eliminate execution/governance sentiment risk.

02

Market read

Company-specific governance/leadership catalyst with reaffirmed financial outlook; likely sentiment-driven volatility rather than a fundamental guidance reset.

03

What to watch

Traders should watch for any subsequent filings (e.g., 8-K) detailing transition mechanics, board committee changes, and whether the interim CEO appointment affects near-term commercial execution.

Relevance 7/10Novelty 8/10Timing: effective immediately (after-hours/PRNewswire publication)

Background

Perrigo announced a CEO change: Patrick Lockwood-Taylor resigned as President/CEO and board member; Albert A. Manzone was appointed interim CEO and interim President effective immediately.

Company-level read

Ticker impact

$PRGONeutralMedium confidence
Context

Perrigo appointed Albert A. Manzone as interim President/CEO after Patrick Lockwood-Taylor’s resignation for personal conduct, effective immediately.

Expected impact

Likely modest volatility around governance headlines, with direction dependent on investor confidence in continuity and outlook credibility.

Evidence & confidence

The article is a primary corporate governance/leadership event (new interim CEO) but does not change financial guidance; it also states the conduct did not involve business/financial reporting.

Market effects

Sector

May increase scrutiny of consumer self-care/OTC peers’ leadership and governance practices, but no direct sector policy change is disclosed.

Regional

Limited; Perrigo is Dublin-based but the catalyst is company-specific and US-listed.

Global

Low; no cross-border deal, regulator action, or supply-chain disruption is announced.

Counterpoint

What could challenge this read

Because the company reaffirmed its full-year 2026 outlook and the board says the conduct was unrelated to operations/financial reporting, the market may quickly refocus on execution rather than governance risk.

Key entities

  • company
    Perrigo Company plc

    Consumer self-care/OTC health products company announcing interim CEO appointment and CEO resignation.

  • person
    Albert A. Manzone

    Board member appointed interim President and CEO effective immediately.

  • person
    Patrick Lockwood-Taylor

    Resigned as President and CEO and as a board member; board cited personal conduct inconsistent with code of conduct.

  • person
    Orlando D. Ashford

    Board Chair commenting on values, transition, and outlook confidence.

Read at source← All news

Related articles

AUG 22
$PRGOMedAI 8/10

This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.

Perrigo (PRGO) reported weak Q2 2026 earnings with a 3.1% sales decline and 21% drop in core earnings. The company's gross and operating margins also fell. Despite paying a $0.29 dividend, risks include weak performance, asset sales, and leadership uncertainty following the abrupt departure of its CEO. Investors are advised to wait for a new CEO's plan before considering the stock.

yahoo.com3 min
AUG 9
$PRGOMed

Perrigo Q2 Earnings Call Highlights

Perrigo (PRGO) reported weaker Q2 self-care and specialty-care demand in Europe and lower store-brand minoxidil and Mederma comparisons, while U.S. OTC volumes turned positive in late July. Infant formula revenue rose 23% YoY. Core adjusted gross margin fell 250 bps to 37%. Perrigo sold Dermacosmetics for $359M, using proceeds to reduce debt, and reiterated its 2026 outlook, including about -$0.60 EPS from under-absorption.

yahoo.com4 min
AUG 5
$PRGOMedAI 8/10

Why is Perrigo stock surging today?

Investing.com reports Perrigo (PRGO) shares rose 24.4% to $13.41 after the company posted Q2 2026 results above analyst estimates. All-in adjusted diluted EPS was $0.50 versus $0.34 expected, and revenue was about $1.02B versus $1.01B. Perrigo cited cost savings and its Three-S strategy, reaffirmed 2026 EPS guidance, and said €305.6M from the Dermacosmetics sale will aid debt reduction.

investing.com4 min
AUG 5
$PRGOMed

PERRIGO Co plc (PRGO): Results of Operations and Financial Condition

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S. store-brand OTC and key European brands • Streamlined

SEC EDGAR 8-K6 min